I think this would qualify:
Business Summary
BRIEF: AMRI, an integrated chemistry outsourcing company, offers a broad range of chemistry research and development services to pharmaceutical and biotechnology companies involved in drug discovery & development. For the 6 months ended 06/30/00, revenues rose 53% to $28.7M. Net income rose 63% to $10.3M. Results reflect a greater number of projects under contract due to an increase in the number of scientific staff, and higher contract revenue margins.
Albany Molecular Research, Inc. Named Second Best Small Company in America by Forbes
(BusinessWire, N/A)
ALBANY, N.Y.--(BUSINESS WIRE)--Oct. 17, 2000--Albany Molecular Research, Inc. (NASDAQ:AMRI) has been named number two in the Forbes magazine annual listing of the "200 Best Small Companies in America."
The Forbes rankings are based on measures of profitability, as well as growth in sales and earnings per share (EPS). Companies with sales between $5 million and $350 million are eligible for the list.
In order to make the list, companies must pass through a series of financial benchmarks, according to Forbes. To make the first cut, a company must have five-year sales and EPS growth rates of at least 5 percent, as well as net income over $1 million during the past four quarters. To pare down the list, Forbes then analyzed over 300 annual reports and 10-Q's, looking for potential warning signs and grounds for disqualification.
For AMRI, Forbes reported an 80 percent average five-year sales growth rate and 55 percent sales growth rate over the last twelve months. The magazine highlighted AMRI's average five-year EPS growth of 155 percent, and EPS growth of 67 percent in the last twelve months. Forbes cited AMRI's zero debt as a factor contributing to the company's profitability. Additionally, Forbes reported a 53 percent operating margin, 33 percent average five-year return on equity, and 17 percent return on equity in the last twelve months, as other measures of the company's profitability.
"To be named the second best small company in America by Forbes is a great honor for the company, our employees and our shareholders," says Chairman and CEO Thomas E. D'Ambra, Ph.D. "This is a wonderful reflection of the efforts of our outstanding people, and their dedication to our customers and the goals of our business. Our goal is to build on our position as the leading chemistry research-based business in the life sciences sector. As much as we are proud of our achievements to date and the recognition we are receiving, this is a great opportunity to rededicate ourselves to even greater accomplishments to come. This is also an opportunity to publicly thank our many employees, at all levels of the company, for their efforts, which are reflected in this recognition."
AMRI's inclusion on the Forbes list marks the second time in less than six months that the company has been recognized by a national business publication. In May 2000, Albany Molecular Research was listed fourth on Business Week's list of the top 100 growth companies.
The Forbes list of the 200 Best Small Companies in America appears in the October 30 issue, which is currently on newsstands.
Albany Molecular Research, Inc. (AMRI) is a chemistry research and development company specializing in pharmaceutical, biotechnology and life sciences applications. The company performs comprehensive chemistry research, from drug discovery and development to commercial manufacturing and provides chemistry support to many of the leading pharmaceutical and biotechnology companies. AMRI also conducts its own research and development, using proprietary platform technologies. The company's research has led to several existing and pending patents, including two key patents for the active ingredient in the non-sedating antihistamine Allegra(R). Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. The Company's actual results may differ materially from such forward-looking statements. Factors that could cause such differences include, but are not limited to, the Company's ability to attract and retain experienced scientists, trends in pharmaceutical and biotechnology companies outsourcing chemical research and development, sales of Allegra(R) and the Company's receipt of significant royalties from the Allegra(R) license agreement, the Company's ability to enforce its intellectual property and technology, the Company's ability to take advantage of proprietary technology and expand the scientific tools available to it, the Company's strategic investments to perform as expected, the Company's ability to successfully complete its ongoing expansion projects on schedule, and the Company's ability to effectively manage its growth, as well as those discussed in the Company's final prospectus as filed with the Securities and Exchange Commission on October 5, 2000 and in the Company's other SEC filings.
CONTACT: Albany Molecular Research, Inc.
David K. Albert, 518/464-0279 (ext. 2229)
Also, not quite pick and shovels but has phoenix behavior:
OSIP
Business Summary
BRIEF: OSI Pharmaceuticals, Inc. utilizes a platform of proprietary technologies in order to discover and develop novel, small molecule compounds for the treatment of major human diseases. For the 9 months ended 6/30/00, revenues increased 35% to $22.2M. Net loss decreased 29% to $4.5M. Revenues reflect the inclusion of a $3.5M technology access fee. Lower loss also reflects the inclusion of a $3.7M gain on the sale of business. |
